Mind Medicine Australia Geelong Chapter Opening & Trivia Night
Mind Medicine Australia is thrilled to announce our Geelong Chapter Opening Night at 6:30pm on Thursday July 22nd at Bells Beach Brewing Shed 2/22 Baines Cres, Torquay VIC 3228.
This event is an important opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
The event will open with a presentation and introduction to Mind Medicine Australia from Dr Jossy Antony, Dr Alana Roy and Geelong Chapter Leader Tommy Moore.
Following the presentation, enjoy an entertaining trivia game with prizes from our sponsors!
Trivia will conclude at 8.30pm with final winners announced, and an opportunity to ask questions and network with fellow chapter members and Mind Medicine Australia staff.
This event is free of charge. However, bookings are essential. MMA is a charity organisation, and we welcome your generous donations to ensure we can achieve our critical mission of making these treatments available and accessible to all Australians in need.
Please click here to make a tax-deductible donation.
Event Details:
- Venue: Bells Beach Brewing – Shed 2/22 Baines Cres, Torquay VIC 3228
- Date: Thursday 22nd of July 2021
- Time: 6:30pm – 9pm
- Tickets: FREE – Food and beverage will be available for purchase at the venue.
About Mind Medicine Australia
Mind Medicine Australia is Australia’s leading not-for-profit organisation working towards the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic, through expanding the treatment options available to medical practitioners and their patients.
Psychedelic-assisted therapies offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce outstanding remission rates, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2022 in some jurisdictions.
The wave of clinical psychedelic research and regulatory support is rapidly building, with psychedelic-assisted treatments also becoming available through Special Access Schemes around the world.
About Medicinal MDMA
Psychedelic-assisted therapies offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2021 in some jurisdictions.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
Many thanks to Mind Medicine Australia’s Geelong Chapter for facilitating this event. Click here for more details or to join the Chapter!
The Presenters
Dr Jossy Antony
Jossy Antony is a General Adult Psychiatrist who works full time and runs a private Mental health clinic called Reflect Health in Geelong. He completed Membership from UK and Fellowship from Australia in Psychiatry. He started his clinic last year with the intention to provide a holistic nurturing space for mental health assessment and treatment. He is passionate about his own inner journey. He has a special interest in ADHD but wants to expand into trauma as well after he was inspired by Bessel Van der Kolk and Gabor mate. He also has an interest in Nutritional Psychiatry. He is currently doing a Certificate in Psychedelic Assisted Psychotherapy through Mind Medicine Australia.
Dr Alana Roy
Ph. D Psychology, B. A Social Work (MHSW)
Dr Alana Roy is a psychologist, social worker and therapist and has spent the last 13 years working in mental health, suicide prevention, trauma, sexual abuse, family violence and the disability sector. Alana has worked with borderline personality and dissociative identity disorder in various roles in the community such as: Rape Crisis Centres with victims of ritual abuse, childhood and adult sexual assault, supporting women in the sex industry, survivors of human trafficking and now as a psychedelic integration specialist.
Alana focuses on harm reduction, community and connection. She is dedicated to psychedelic-assisted psychotherapy and plant medicines. She has engaged with, and provides integration therapeutic support services for communities across Australia. Alana works at several universities as a Research Fellow and supervisor of students on placement. Alana passionately advocates for public policy, community education and legislative changes so that these treatments are regulated and supported by a strong, connected and skilled sector.
Learn more about Alana’s experiences in: Psychedelic Medicines: How My Journey Into The Jungle Changed My Life